Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products.
The company’s vision is to contribute to better and cheaper medicine through porous silica. In Chromatography, the aim is to make diabetes drugs and other peptide-based drugs available to more patients by providing products that can lower the production costs at the manufacturers. In Drug Development, the company’s platform for inhalation is developed to give patients with severe lung diseases access to new or improved treatments.
2004
Served areaWorldwide
Headcount20
HeadquartersForskargatan 20 G, 15136 Södertälje – Sweden
36,150,000
IPOOct. 30, 2015
Stock exchange(s)Nasdaq Stockholm